Review decision, February 2008
Review of NICE Technology Appraisal Guidance No 86, on the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
During consultation, the majority of comments received by the Institute agreed with the proposal, that it was appropriate for the review to go ahead.
After consideration of all of the comments, the Institute?s Guidance Executive decided to proceed with this proposal.
The responses received during the review proposal consultation are listed below.
7 February 2008
This page was last updated: 30 December 2010